NO327245B1 - Orale farmasoytiske doseringsformer omfattende en protonpumpeinhibitor og et NSAID, fremgangsmate for fremstilling samt anvendelse derav. - Google Patents
Orale farmasoytiske doseringsformer omfattende en protonpumpeinhibitor og et NSAID, fremgangsmate for fremstilling samt anvendelse derav. Download PDFInfo
- Publication number
- NO327245B1 NO327245B1 NO19974069A NO974069A NO327245B1 NO 327245 B1 NO327245 B1 NO 327245B1 NO 19974069 A NO19974069 A NO 19974069A NO 974069 A NO974069 A NO 974069A NO 327245 B1 NO327245 B1 NO 327245B1
- Authority
- NO
- Norway
- Prior art keywords
- dosage form
- tablet
- pellets
- proton pump
- coating layer
- Prior art date
Links
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title claims description 110
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims description 110
- 239000002552 dosage form Substances 0.000 title claims description 97
- 229940126409 proton pump inhibitor Drugs 0.000 title claims description 91
- 239000000612 proton pump inhibitor Substances 0.000 title claims description 91
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title description 16
- 239000010410 layer Substances 0.000 claims description 184
- 239000003826 tablet Substances 0.000 claims description 128
- 239000008188 pellet Substances 0.000 claims description 115
- 239000002702 enteric coating Substances 0.000 claims description 93
- 238000009505 enteric coating Methods 0.000 claims description 93
- 239000002253 acid Substances 0.000 claims description 37
- 239000008187 granular material Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 32
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 229960000381 omeprazole Drugs 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 16
- 239000011247 coating layer Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 229960002702 piroxicam Drugs 0.000 claims description 14
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 14
- 230000002496 gastric effect Effects 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 12
- 239000007888 film coating Substances 0.000 claims description 12
- 238000009501 film coating Methods 0.000 claims description 12
- 229960002009 naproxen Drugs 0.000 claims description 12
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 239000007900 aqueous suspension Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 8
- 229960001680 ibuprofen Drugs 0.000 claims description 8
- 229960001259 diclofenac Drugs 0.000 claims description 7
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 7
- 238000013265 extended release Methods 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 159000000011 group IA salts Chemical class 0.000 claims description 5
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical group CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 5
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical group COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 229960005019 pantoprazole Drugs 0.000 claims description 4
- 239000007916 tablet composition Substances 0.000 claims description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 3
- 239000007963 capsule composition Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000002662 enteric coated tablet Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 239000011162 core material Substances 0.000 description 41
- 239000012530 fluid Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 239000013543 active substance Substances 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 16
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 16
- KWORUUGOSLYAGD-UHFFFAOYSA-N magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C.N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-UHFFFAOYSA-N 0.000 description 16
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 15
- 238000000576 coating method Methods 0.000 description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 13
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 13
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 13
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 13
- 239000011230 binding agent Substances 0.000 description 12
- 238000005469 granulation Methods 0.000 description 12
- 230000003179 granulation Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 239000000454 talc Substances 0.000 description 12
- 229910052623 talc Inorganic materials 0.000 description 12
- 235000012222 talc Nutrition 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 11
- 239000000654 additive Substances 0.000 description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- -1 piperidino, morpholino Chemical group 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000004014 plasticizer Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000007906 compression Methods 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 8
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 229950008882 polysorbate Drugs 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 239000001069 triethyl citrate Substances 0.000 description 7
- 235000013769 triethyl citrate Nutrition 0.000 description 7
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000011575 calcium Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 239000000395 magnesium oxide Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 230000000181 anti-adherent effect Effects 0.000 description 3
- 239000003699 antiulcer agent Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 229920001688 coating polymer Polymers 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000011116 calcium hydroxide Nutrition 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000011262 co‐therapy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960003174 lansoprazole Drugs 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical group [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010062532 Erosive duodenitis Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229910020038 Mg6Al2 Inorganic materials 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960001850 droxicam Drugs 0.000 description 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960003240 floctafenine Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003022 phthalic acids Chemical class 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003218 pyrazolidines Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600070A SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | New oral pharmaceutical dosage forms |
| PCT/SE1996/001735 WO1997025064A1 (en) | 1996-01-08 | 1996-12-20 | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO974069D0 NO974069D0 (no) | 1997-09-04 |
| NO974069L NO974069L (no) | 1997-10-17 |
| NO327245B1 true NO327245B1 (no) | 2009-05-18 |
Family
ID=20400968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19974069A NO327245B1 (no) | 1996-01-08 | 1997-09-04 | Orale farmasoytiske doseringsformer omfattende en protonpumpeinhibitor og et NSAID, fremgangsmate for fremstilling samt anvendelse derav. |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US6365184B1 (xx) |
| EP (3) | EP1352660A1 (xx) |
| JP (1) | JP4638964B2 (xx) |
| KR (1) | KR100483870B1 (xx) |
| CN (1) | CN1116899C (xx) |
| AR (1) | AR005282A1 (xx) |
| AT (1) | ATE242006T1 (xx) |
| AU (1) | AU712571B2 (xx) |
| BR (1) | BR9607476A (xx) |
| CA (1) | CA2213987C (xx) |
| CZ (1) | CZ294255B6 (xx) |
| DE (1) | DE69628551T2 (xx) |
| DK (1) | DK0814839T3 (xx) |
| EE (1) | EE04003B1 (xx) |
| ES (1) | ES2201211T3 (xx) |
| HK (2) | HK1001761A1 (xx) |
| HU (1) | HU228569B1 (xx) |
| IL (1) | IL121650A (xx) |
| IS (1) | IS2368B (xx) |
| MX (1) | MX9706767A (xx) |
| MY (1) | MY119212A (xx) |
| NO (1) | NO327245B1 (xx) |
| NZ (1) | NZ325975A (xx) |
| PL (1) | PL187074B1 (xx) |
| PT (1) | PT814839E (xx) |
| RU (1) | RU2158138C2 (xx) |
| SA (1) | SA96170540B1 (xx) |
| SE (1) | SE9600070D0 (xx) |
| SI (1) | SI0814839T1 (xx) |
| SK (1) | SK283871B6 (xx) |
| TR (1) | TR199700915T1 (xx) |
| TW (1) | TW452495B (xx) |
| UA (1) | UA46012C2 (xx) |
| WO (1) | WO1997025064A1 (xx) |
| ZA (1) | ZA9610936B (xx) |
Families Citing this family (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| US6623759B2 (en) * | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
| US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| FR2771291B1 (fr) * | 1997-11-21 | 2000-02-25 | Ethypharm Lab Prod Ethiques | Spheroides, procede de preparation et compositions pharmaceutiques |
| ES2559766T3 (es) * | 1998-05-18 | 2016-02-15 | Takeda Pharmaceutical Company Limited | Comprimidos disgregables en la boca |
| ES2237121T3 (es) * | 1998-07-28 | 2005-07-16 | Takeda Pharmaceutical Company Limited | Preparacion solida disgregable rapidamente. |
| DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
| US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
| US6852739B1 (en) * | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| SE0000774D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| AU2001257022B2 (en) * | 2000-04-13 | 2005-02-03 | Mayo Foundation For Medical Education And Research | Abeta 42 lowering agents |
| US6761895B2 (en) * | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
| US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050118138A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
| US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
| US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US7737147B2 (en) * | 2000-07-27 | 2010-06-15 | Thomas Nadackal Thomas | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors |
| US7029701B2 (en) * | 2000-09-11 | 2006-04-18 | Andrx Pharmaceuticals, Llc | Composition for the treatment and prevention of ischemic events |
| US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| MXPA03011031A (es) * | 2001-05-30 | 2004-07-08 | Euro Celtique Sa | Composicion farmaceutica. |
| EA006398B1 (ru) * | 2001-06-01 | 2005-12-29 | Поузен Инк. | Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| KR100425226B1 (ko) * | 2001-07-03 | 2004-03-30 | 주식회사 팜트리 | 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법 |
| SE0102993D0 (sv) * | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| EP1438018B1 (en) | 2001-09-28 | 2010-08-11 | McNeil-PPC, Inc. | Fondant-based pharmaceutical composition |
| GB2380937A (en) * | 2001-10-18 | 2003-04-23 | David Ian Slovick | Method of dispensing a plurality of medical substances into capsules |
| FR2831820B1 (fr) * | 2001-11-05 | 2004-08-20 | Ethypharm Sa | Comprime orodispersible presentant une grande homogeneite et son procede de preparation |
| ES2198195B1 (es) * | 2001-12-18 | 2004-10-01 | Laboratorios Del Dr. Esteve, S.A. | Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido. |
| US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| WO2004010945A2 (en) * | 2002-07-29 | 2004-02-05 | Nitromed, Inc. | Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| CA2493618A1 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
| DE10244504A1 (de) * | 2002-09-25 | 2004-04-08 | Capsulution Nanoscience Ag | Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| FR2845917B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire |
| US20080145424A1 (en) * | 2002-10-24 | 2008-06-19 | Enos Phramaceuticals, Inc. | Sustained release L-arginine formulations and methods of manufacture and use |
| US20060029668A1 (en) * | 2002-10-24 | 2006-02-09 | Ron Eyal S | Sustained release L-arginine formulations and methods of manufacture and use |
| CA2503284A1 (en) * | 2002-10-24 | 2004-05-06 | Enos Pharmaceuticals, Inc. | Sustained release l-arginine formulations and methods of manufacture and use |
| US20050288373A1 (en) * | 2002-10-24 | 2005-12-29 | Ron Eyal S | Methods of treating various conditions by administration of sustained release L-arginine |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
| AU2003288608A1 (en) * | 2002-12-20 | 2004-07-14 | Ranbaxy Laboratories Limited | Controlled release, multiple unit drug delivery systems |
| WO2004060355A1 (en) * | 2002-12-26 | 2004-07-22 | Pozen Inc. | Multilayer Dosage Forms Containing NSAIDs and Triptans |
| WO2004062552A2 (en) * | 2003-01-09 | 2004-07-29 | Galephar M/F | Pharmaceutical composition containing a nsaid and a benzimidazole derivative |
| WO2004064815A1 (en) * | 2003-01-21 | 2004-08-05 | Smartrix Technologies Inc. | Oral dosage formulation |
| WO2004066924A2 (en) * | 2003-01-24 | 2004-08-12 | Andrx Labs Llc | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
| EP1462098B1 (en) * | 2003-03-03 | 2007-07-04 | SPRL Franpharma | Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin |
| CN101524336B (zh) * | 2003-05-08 | 2013-12-18 | 塔科达有限责任公司 | 含有泮托拉唑作为活性成分的剂型 |
| CL2004000983A1 (es) * | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
| PE20050150A1 (es) * | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
| EP1651195A4 (en) * | 2003-07-11 | 2007-10-03 | Myriad Genetics Inc | PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
| AU2004279298B2 (en) * | 2003-09-29 | 2009-01-29 | Palmetto Pharmaceuticals, Llc | Sustained release L-arginine formulations and methods of manufacture and use |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| EP1667681A4 (en) | 2003-10-03 | 2009-09-30 | Astron Res Pvt Ltd | NEW TRANSMUCOSAL ADMINISTRATION SYSTEM |
| WO2005044240A2 (en) * | 2003-10-31 | 2005-05-19 | Dexcel, Ltd. | Stable lansoprazole formulation |
| US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| WO2005074930A1 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids |
| US20050249806A1 (en) * | 2004-02-10 | 2005-11-10 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug |
| US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
| US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
| US20070293538A1 (en) * | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
| WO2005108683A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| WO2006009602A2 (en) | 2004-06-16 | 2006-01-26 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| US20050281876A1 (en) | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
| EA014443B1 (ru) * | 2004-06-29 | 2010-12-30 | Никомед Данмарк Апс | Фармацевтическая композиция (варианты) и способ ее производства |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| BRPI0514303A (pt) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | composição farmacêutica e método para tratar distúrbios neurodegenerativos |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006137839A2 (en) * | 2004-08-24 | 2006-12-28 | Merck & Co., Inc. | Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |
| US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| EP1846037A4 (en) * | 2005-01-24 | 2008-03-12 | Palmetto Pharmaceuticals Llc | METHODS OF TREATING VARIOUS CONDITIONS BY ADMINISTERING L-ARGININE WITH PROLONGED RELEASE |
| US20060177504A1 (en) * | 2005-02-08 | 2006-08-10 | Renjit Sundharadas | Combination pain medication |
| US9149439B2 (en) * | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
| US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
| US20070003490A1 (en) * | 2005-06-29 | 2007-01-04 | Medical Futures Inc. | Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against NSAID gastropathy |
| US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| CN101257800B (zh) * | 2005-07-18 | 2012-07-18 | 好利用医疗公司 | 包含法莫替丁和布洛芬的药物 |
| US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
| US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| EP1909777A2 (en) * | 2005-07-22 | 2008-04-16 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
| US20080085314A1 (en) * | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| US20080166407A1 (en) * | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| AU2006275476A1 (en) * | 2005-08-01 | 2007-02-08 | Alpharma Inc. | Alcohol resistant pharmaceutical formulations |
| AR057181A1 (es) * | 2005-11-30 | 2007-11-21 | Astra Ab | Nueva forma de dosificacion de combinacion |
| WO2007075980A2 (en) * | 2005-12-20 | 2007-07-05 | Teva Pharmaceutical Industries Ltd. | Lansoprazole orally disintegrating tablets |
| EP1813275A1 (en) * | 2005-12-20 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Lansoprazole orally disintegrating tablets |
| US20070154542A1 (en) * | 2005-12-30 | 2007-07-05 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
| ES2562059T3 (es) * | 2006-01-27 | 2016-03-02 | Yale University | Inhibidor de acción rápida de la secreción de ácido gástrico |
| US8512761B2 (en) * | 2006-01-27 | 2013-08-20 | Yale University | Fast acting inhibitor of gastric acid secretion |
| EP1837016A3 (en) * | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
| EP1834634A3 (en) * | 2006-03-08 | 2007-10-03 | Rentschler Pharma GmbH | Pharmaceutical multiple-unit composition |
| CA2647497C (en) * | 2006-04-04 | 2016-01-12 | Cogentus Pharmaceuticals, Inc. | Oral dosage forms including an antiplatelet agent and an acid inhibitor |
| US9532945B2 (en) * | 2006-04-04 | 2017-01-03 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor |
| US20090068263A1 (en) * | 2006-04-20 | 2009-03-12 | Themis Laboratories Private Limited | Multiple unit compositions |
| EP2614818A1 (en) * | 2006-04-28 | 2013-07-17 | Wockhardt Limited | Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor |
| WO2008006099A2 (en) * | 2006-07-07 | 2008-01-10 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| WO2008018825A1 (en) * | 2006-08-10 | 2008-02-14 | Astrazeneca Ab | Oral polyvinyl alcohol capsules comprising proton pump inhibitors |
| EP2063873A2 (en) * | 2006-08-31 | 2009-06-03 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
| CA2665226C (en) * | 2006-10-05 | 2014-05-13 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| US8394415B2 (en) * | 2006-11-21 | 2013-03-12 | Mcneil-Ppc, Inc | Modified release analgesic suspensions |
| ITMI20062290A1 (it) * | 2006-11-28 | 2008-05-29 | Monteres S R L | Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente |
| US20080286343A1 (en) * | 2007-05-16 | 2008-11-20 | Dzenana Cengic | Solid form |
| WO2008140459A1 (en) * | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
| WO2008140460A1 (en) * | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
| US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
| CA2600147A1 (en) * | 2007-06-11 | 2008-12-11 | Nathan Bryson | Combination for treatment of diabetes mellitus |
| US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
| CA2713197C (en) * | 2008-01-25 | 2016-10-04 | Duo-Ge | Combinations of oral medicaments bonded by a wrapping |
| FR2926724B1 (fr) * | 2008-01-25 | 2010-06-18 | Duo Ge | Nouvelle forme pharmaceutique orale. |
| FR2926723B1 (fr) * | 2008-01-25 | 2010-06-18 | Duo Ge | Associations pharmaceutiques orales. |
| US20090252791A1 (en) * | 2008-04-02 | 2009-10-08 | Venkata Nookaraju Sreedharala | Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug |
| EP2306998A4 (en) * | 2008-06-20 | 2011-06-15 | Alphapharm Pty Ltd | PHARMACEUTICAL FORMULATION |
| WO2010018593A2 (en) * | 2008-07-03 | 2010-02-18 | Torrent Pharmaceuticals Ltd. | Gastric acid resistant benzimidazole multiple unit tablet composition |
| US8807070B2 (en) * | 2008-08-07 | 2014-08-19 | Vector Corporation | Rotor processor for dry powders |
| US20100034967A1 (en) * | 2008-08-07 | 2010-02-11 | Vector Corporation | Dry polymer layering using a rotor processor |
| US20100034968A1 (en) * | 2008-08-07 | 2010-02-11 | Vector Corporation | Polymer coating process using dry glidant in a rotor processor |
| US20110144207A1 (en) * | 2008-08-14 | 2011-06-16 | Shasun Chemicals And Drugs Limited | Aryl alkyl carboxylic acid salts, process for preparation and dosage forms |
| MX2011002515A (es) | 2008-09-09 | 2011-04-07 | Astrazeneca Ab | Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita. |
| US8246988B2 (en) * | 2009-01-05 | 2012-08-21 | Mcneil-Ppc, Inc. | Three layer tablet containing cetirizine, pseudoephedrine, and naproxen |
| WO2010078543A1 (en) * | 2009-01-05 | 2010-07-08 | Mcneil-Ppc, Inc. | Tablet containing cetirizine pseudoephedrine, and naproxen containing a barrier layer |
| US8252330B2 (en) * | 2009-01-05 | 2012-08-28 | Mcneil-Ppc, Inc. | Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen |
| DK2421525T3 (en) | 2009-04-24 | 2017-09-25 | Iceutica Pty Ltd | DICLOFENACFORMULATION |
| CN103932988A (zh) | 2009-04-24 | 2014-07-23 | 伊休蒂卡有限公司 | 吲哚美辛的新剂型 |
| US20100305163A1 (en) * | 2009-05-20 | 2010-12-02 | Pramod Dattatray Yedurkar | Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs |
| WO2010151216A1 (en) | 2009-06-25 | 2010-12-29 | Astrazeneca Ab | Method for treating a patient at risk for developing an nsaid-associated ulcer |
| EA021112B1 (ru) * | 2009-06-25 | 2015-04-30 | Поузен Инк. | Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии |
| BRPI1016013A2 (pt) * | 2009-06-29 | 2016-04-26 | Mcneil Ppc Inc | tablete farmacêutico contendo uma cápsula preenchida com líquido. |
| RU2010108361A (ru) * | 2010-03-09 | 2011-09-20 | Гаврилова Эмилия Евгеньевна (RU) | Набор лечебных средств |
| WO2011144994A1 (en) * | 2010-05-21 | 2011-11-24 | Lupin Limited | Pharmaceutical compositions of nsaid and acid inhibitor |
| JPWO2012018056A1 (ja) * | 2010-08-03 | 2013-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 圧縮組成物 |
| DE102010052847A1 (de) | 2010-11-29 | 2012-05-31 | Temmler Werke Gmbh | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
| WO2012074110A1 (ja) | 2010-12-03 | 2012-06-07 | 武田薬品工業株式会社 | 口腔内崩壊錠 |
| JP5902194B2 (ja) | 2010-12-16 | 2016-04-13 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物 |
| CN103415285A (zh) * | 2011-02-02 | 2013-11-27 | 雅来制药有限责任公司 | 包含阿片样激动剂和被隔离的拮抗剂的药物组合物 |
| BR112013026195A2 (pt) | 2011-04-12 | 2016-11-29 | Novo Nordisk As | derivados de glp-1 duplamente acilados |
| TR201103752A2 (tr) | 2011-04-18 | 2012-11-21 | Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. | Tiyokolşikozit, diklofenak ve lansoprazol kombinasyonları. |
| JP2014516080A (ja) * | 2011-06-08 | 2014-07-07 | エスティーアイ ファーマ， エルエルシー | 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤 |
| CN102406938A (zh) * | 2011-11-29 | 2012-04-11 | 北京阜康仁生物制药科技有限公司 | 一种抗血栓的药物组合物 |
| US9433632B2 (en) | 2011-11-30 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Dry coated tablet |
| BR112014016085A8 (pt) | 2011-12-28 | 2017-07-04 | Pozen Inc | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico |
| EP2827843B1 (en) | 2012-03-20 | 2016-05-25 | Laboratorios Bagó S.A. | Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them |
| HUE039406T2 (hu) | 2012-03-22 | 2018-12-28 | Novo Nordisk As | GLP-1 peptid készítményei és azok elõállítása |
| HRP20231613T1 (hr) | 2012-03-22 | 2024-03-15 | Novo Nordisk A/S | Pripravci koji sadrže sredstvo za unošenje i njihova priprava |
| PT2827845T (pt) | 2012-03-22 | 2019-03-29 | Novo Nordisk As | Composições compreendendo um agente de entrega e sua preparação |
| KR101907690B1 (ko) * | 2012-04-12 | 2018-10-15 | 한미약품 주식회사 | 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 약제학적 복합제제 및 이의 제조방법 |
| KR101378973B1 (ko) * | 2012-04-13 | 2014-03-28 | 한미약품 주식회사 | 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법 |
| US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
| KR20160010595A (ko) | 2013-05-21 | 2016-01-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 구강내 붕괴정 |
| WO2015150943A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Pharmaceutical composition of nsaid and ppi or salt thereof |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| KR101723266B1 (ko) * | 2014-08-13 | 2017-04-05 | 영남대학교 산학협력단 | 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 경구용 속방형 조성물 및 그 제조방법 |
| CN104208039B (zh) * | 2014-08-26 | 2017-05-03 | 杭州新诺华医药有限公司 | 一种萘普生埃索美拉唑镁肠溶制剂及制备方法 |
| SI3236952T1 (sl) * | 2014-12-23 | 2019-11-29 | Krka D D Novo Mesto | Farmacevtski sestavek v obliki tablet |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| PE20180605A1 (es) | 2015-07-30 | 2018-04-09 | Takeda Pharmaceuticals Co | Tableta |
| CN106668017A (zh) * | 2015-11-11 | 2017-05-17 | 上海星泰医药科技有限公司 | 萘普生和埃索美拉唑镁复方肠溶胶囊及其制备方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TR201618765A2 (tr) | 2016-12-16 | 2018-07-23 | Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi | Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları. |
| TR201718099A2 (tr) | 2017-11-16 | 2019-06-21 | Mehmet Nevzat Pisak | Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar |
| WO2019135725A1 (en) | 2018-01-03 | 2019-07-11 | Pisak Mehmet Nevzat | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation |
| BR112020014624A2 (pt) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| WO2019240310A1 (ko) * | 2018-06-14 | 2019-12-19 | 한국유나이티드제약 주식회사 | 아세클로페낙과 에스오메프라졸을 포함하는 복합제제 및 그 제조방법 |
| RU2732297C2 (ru) * | 2018-11-14 | 2020-09-15 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Производные нестероидных противовоспалительных средств |
| EP4070789A4 (en) * | 2020-01-23 | 2024-01-24 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITE FORMULATION WITH PROTON PUMP INHIBITOR AND ANTACID |
| KR20210127108A (ko) * | 2020-04-13 | 2021-10-21 | 에이치케이이노엔 주식회사 | 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물 |
| CN116648239A (zh) * | 2021-08-26 | 2023-08-25 | 宁德时代新能源科技股份有限公司 | 液囊、电池单体、电池和用电装置 |
| WO2023129069A2 (en) * | 2021-12-29 | 2023-07-06 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | A pharmaceutical composition comprising naproxen and esomeprazole |
| KR102553713B1 (ko) * | 2022-11-18 | 2023-07-10 | 고덕상 | 미네랄 촉매제를 이용한 양식어류사료 제조방법 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4016744A (en) | 1975-05-28 | 1977-04-12 | Hoffmann-La Roche Inc. | Applied instrumentation providing tabletting compression force |
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
| JPS5598120A (en) | 1979-01-16 | 1980-07-25 | Shin Etsu Chem Co Ltd | Preparation of drug having enteric coating |
| US4263328A (en) | 1979-10-26 | 1981-04-21 | General Foods Corporation | Tableted gasified candy |
| FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4602007A (en) * | 1980-05-08 | 1986-07-22 | Abbott Laboratories | Salicylate culture media for inactivation of bacterial growth inhibitors |
| US4340582A (en) | 1981-01-15 | 1982-07-20 | Abbott Laboratories | Erythromycin base tablets |
| US4377568A (en) | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
| DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| JPS5973529A (ja) | 1982-10-12 | 1984-04-25 | Sankyo Co Ltd | 被覆固形製剤の製造法 |
| US4525339A (en) | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
| US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| GB2132887A (en) | 1982-11-15 | 1984-07-18 | Procter & Gamble | Enteric-coated anti-inflammatory compositions |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| EP0153105B1 (en) | 1984-02-10 | 1992-09-09 | Benzon Pharma A/S | Diffusion coated multiple-units dosage form |
| US4568560A (en) | 1984-03-16 | 1986-02-04 | Warner-Lambert Company | Encapsulated fragrances and flavors and process therefor |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| SE450087B (sv) | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| SE8803822D0 (sv) * | 1988-10-26 | 1988-10-26 | Novel dosage form | |
| SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| US4948581A (en) | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
| US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| IN171746B (xx) * | 1989-11-02 | 1992-12-26 | Mcneil Ppc Inc | |
| US5049674A (en) | 1989-12-20 | 1991-09-17 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
| SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
| DE69131627T2 (de) | 1990-06-20 | 2000-04-27 | Astra Ab Soedertaelje | Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung |
| US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
| JP3142919B2 (ja) | 1991-11-06 | 2001-03-07 | 旭化成株式会社 | セルロース誘導体ラテックス及びその製法 |
| EP0661966B1 (en) * | 1991-12-17 | 2000-07-19 | Biovail Technologies Ltd. | Ulcer prevention and treatment composition and method |
| US5160742A (en) | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| WO1994003160A1 (en) | 1992-08-05 | 1994-02-17 | F.H. Faulding & Co. Limited | Pelletised pharmaceutical composition |
| IT1256345B (it) | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| US5330759A (en) | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
| IT1256450B (it) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| ATE168986T1 (de) | 1993-10-06 | 1998-08-15 | Nicox Sa | Salzetersaüreester mit entzündungshemmender und/oder schmerzlindernder wirkung und verfahren zu deren herstellung |
| JP3017906B2 (ja) | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | 腸溶性コーティング剤分散液 |
| US5798120A (en) | 1993-10-12 | 1998-08-25 | Tokyo Tanabe Company Limited | Enteric granule-containing tablets |
| US5374730A (en) | 1993-11-04 | 1994-12-20 | Torcan Chemical Ltd. | Preparation of omeprazole and lansoprazole |
| GB2285989A (en) | 1994-01-28 | 1995-08-02 | Merck Frosst Canada Inc | Aqueous formulations for enteric coatings |
| DK0759899T3 (da) | 1994-05-10 | 1999-12-20 | Nicox Sa | Nitroforbindelser og sammensætninger deraf med antiinflammatoriske, analgetiske og antitrombotiske aktiviteter |
| SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| DK1078628T3 (da) | 1994-07-08 | 2009-02-23 | Astrazeneca Ab | Tabletteret flerenhedsdoseringsform |
| US5763422A (en) | 1995-01-27 | 1998-06-09 | Board Of Regents, The University Of Texas System | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| JPH08301763A (ja) | 1995-04-28 | 1996-11-19 | Dainippon Pharmaceut Co Ltd | 易溶性粉末状医薬組成物およびその製造方法 |
| US5955451A (en) | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| WO1998022117A1 (en) | 1996-11-22 | 1998-05-28 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials |
| EP0941102A1 (en) | 1996-11-22 | 1999-09-15 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid |
| US6383982B1 (en) * | 1999-05-11 | 2002-05-07 | Mitsui Chemicals, Inc. | Color developer composition, aqueous dispersion, recording sheet and color developing ink |
| HUP0201637A3 (en) * | 1999-06-07 | 2004-05-28 | Altana Pharma Ag | Novel preparation and administration form comprising an acid-labile active compound |
| SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| AR057181A1 (es) | 2005-11-30 | 2007-11-21 | Astra Ab | Nueva forma de dosificacion de combinacion |
-
1996
- 1996-01-08 SE SE9600070A patent/SE9600070D0/xx unknown
- 1996-12-20 IL IL12165096A patent/IL121650A/xx not_active IP Right Cessation
- 1996-12-20 UA UA97104950A patent/UA46012C2/uk unknown
- 1996-12-20 EE EE9700194A patent/EE04003B1/xx not_active IP Right Cessation
- 1996-12-20 ES ES96944724T patent/ES2201211T3/es not_active Expired - Lifetime
- 1996-12-20 CZ CZ19972748A patent/CZ294255B6/cs not_active IP Right Cessation
- 1996-12-20 PT PT96944724T patent/PT814839E/pt unknown
- 1996-12-20 CA CA002213987A patent/CA2213987C/en not_active Expired - Fee Related
- 1996-12-20 SI SI9630626T patent/SI0814839T1/xx unknown
- 1996-12-20 MX MX9706767A patent/MX9706767A/es unknown
- 1996-12-20 KR KR1019970706234A patent/KR100483870B1/ko not_active IP Right Cessation
- 1996-12-20 RU RU97116843/14A patent/RU2158138C2/ru not_active IP Right Cessation
- 1996-12-20 JP JP52512997A patent/JP4638964B2/ja not_active Expired - Fee Related
- 1996-12-20 CN CN96193595A patent/CN1116899C/zh not_active Expired - Fee Related
- 1996-12-20 DK DK96944724T patent/DK0814839T3/da active
- 1996-12-20 SK SK1177-97A patent/SK283871B6/sk not_active IP Right Cessation
- 1996-12-20 AT AT96944724T patent/ATE242006T1/de active
- 1996-12-20 EP EP03011903A patent/EP1352660A1/en not_active Ceased
- 1996-12-20 WO PCT/SE1996/001735 patent/WO1997025064A1/en active IP Right Grant
- 1996-12-20 PL PL96322174A patent/PL187074B1/pl not_active IP Right Cessation
- 1996-12-20 TR TR97/00915T patent/TR199700915T1/xx unknown
- 1996-12-20 HU HU9904095A patent/HU228569B1/hu not_active IP Right Cessation
- 1996-12-20 BR BR9607476A patent/BR9607476A/pt not_active IP Right Cessation
- 1996-12-20 EP EP10180339A patent/EP2275139A1/en not_active Withdrawn
- 1996-12-20 EP EP96944724A patent/EP0814839B1/en not_active Expired - Lifetime
- 1996-12-20 NZ NZ325975A patent/NZ325975A/xx not_active IP Right Cessation
- 1996-12-20 DE DE69628551T patent/DE69628551T2/de not_active Expired - Lifetime
- 1996-12-20 AU AU13239/97A patent/AU712571B2/en not_active Ceased
- 1996-12-26 AR ARP960105900A patent/AR005282A1/es active IP Right Grant
- 1996-12-27 TW TW085116137A patent/TW452495B/zh not_active IP Right Cessation
- 1996-12-30 ZA ZA9610936A patent/ZA9610936B/xx unknown
- 1996-12-31 SA SA96170540A patent/SA96170540B1/ar unknown
-
1997
- 1997-01-07 MY MYPI97000059A patent/MY119212A/en unknown
- 1997-08-19 IS IS4546A patent/IS2368B/is unknown
- 1997-09-04 NO NO19974069A patent/NO327245B1/no not_active IP Right Cessation
-
1998
- 1998-02-05 HK HK98100845A patent/HK1001761A1/xx not_active IP Right Cessation
- 1998-11-06 HK HK98111787A patent/HK1017991A1/xx not_active IP Right Cessation
-
1999
- 1999-12-23 US US09/471,958 patent/US6365184B1/en not_active Expired - Lifetime
-
2002
- 2002-03-04 US US10/090,882 patent/US6613354B2/en not_active Expired - Fee Related
-
2003
- 2003-07-14 US US10/620,000 patent/US7488497B2/en not_active Expired - Fee Related
-
2009
- 2009-02-09 US US12/368,076 patent/US8114435B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327245B1 (no) | Orale farmasoytiske doseringsformer omfattende en protonpumpeinhibitor og et NSAID, fremgangsmate for fremstilling samt anvendelse derav. | |
| NO316425B1 (no) | Orale, farmasöytiske doseringsformer innbefattende en protonpumpeinhibitorog et prokinetisk middel, fremgangsmåte for fremstilling av slikedoseringsformer og anvendelse derav | |
| US20100178334A1 (en) | Oral Pharmaceutical Dosage Form Comprising as Active Ingredients a Proton Pump Inhibitor together with Acetyl Salicyclic Acid | |
| NO326656B1 (no) | Orale, farmasoytiske doseringsformer innbefattende en protonpumpeinhibitor og et syrenoytraliserende middel eller alginat, fremgangsmate for fremstilling av slike doseringsformer og anvendelse derav. | |
| US20100330150A1 (en) | Orally Disintegrating Tablet Compositions Comprising Combinations of High and Low-Dose Drugs | |
| NO319999B1 (no) | Tabletterte, brusende multippelenhet-doseringsformer omfattende en protonpumpeinhibitor, fremgangsmate for fremstilling av slike doseringsformer, og anvendelse derav. | |
| JP2004508396A (ja) | 非ステロイド性抗炎症薬およびプロトンポンプ阻害薬を含有する医薬製剤 | |
| WO2004062552A2 (en) | Pharmaceutical composition containing a nsaid and a benzimidazole derivative | |
| KR100602235B1 (ko) | 방출제어형 약제학적 조성물의 제조방법 | |
| BRPI0619391A2 (pt) | forma de dosagem farmacêutica oral, processo para a manufatura de uma forma de dosagem de combinação fixa oral, uso de uma forma de dosagem, e, forma de combinação fixa oral farmacêutica | |
| MX2008006727A (en) | Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |